BRPI0508983A - uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano - Google Patents
uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humanoInfo
- Publication number
- BRPI0508983A BRPI0508983A BRPI0508983-2A BRPI0508983A BRPI0508983A BR PI0508983 A BRPI0508983 A BR PI0508983A BR PI0508983 A BRPI0508983 A BR PI0508983A BR PI0508983 A BRPI0508983 A BR PI0508983A
- Authority
- BR
- Brazil
- Prior art keywords
- azd2171
- taxane
- human
- warm
- vascular permeability
- Prior art date
Links
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 title abstract 6
- 229940123237 Taxane Drugs 0.000 title abstract 6
- 229960002412 cediranib Drugs 0.000 title abstract 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 6
- 241001465754 Metazoa Species 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 4
- 230000001772 anti-angiogenic effect Effects 0.000 title abstract 3
- 230000001603 reducing effect Effects 0.000 title abstract 3
- 230000008728 vascular permeability Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical class OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005855 radiation Effects 0.000 abstract 2
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE ZD2171 OU DE UM SAL DESTE FARMACEUTICAMENTE ACEITáVEL EXCLUINDO UM SAL DE MALEATO DE AZD2171 E UM TAXANO, COMPOSIçãO FARMACêUTICA, KIT, E, MéTODO PARA A PRODUçãO DE UM EFEITO ANTIANGIOGêNICO E/OU DE REUçãO DA PERMEABILIDADE VASCULAR EM UM ANIMAL DE SANGUE QUENTE TAL COMO UM SER HUMANO A presente invenção dis respeito a um método para produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano que está sendo opcionalmente tratado com radiação ionizante, particulamente um método para o tratamento de um cãncer envolvendo um tumor sólido, que compreende a administração de AZD2171 em combinação com um taxano; a uma composição farmacêuica compreendendo AZD2171 e um taxano; a um produto de combinação compreendendo AZD2171 e um taxano para o uso em um método de tratamento de um corpo humano ou animal pela terapia; a um kit compreendendo AZD2171 e um taxano ; ao uso de AZD2171 e um taxano na fabricação de medicamento para o uso na produção de um ifeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano que está sendo opcionalmente tratado com radiação ionizante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0406445.7A GB0406445D0 (en) | 2004-03-23 | 2004-03-23 | Combination therapy |
| PCT/GB2005/001089 WO2005092385A2 (en) | 2004-03-23 | 2005-03-22 | Combination therapy of azd2171 and a taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0508983A true BRPI0508983A (pt) | 2007-08-28 |
Family
ID=32188481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0508983-2A BRPI0508983A (pt) | 2004-03-23 | 2005-03-22 | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070135462A1 (pt) |
| EP (1) | EP1729807B1 (pt) |
| JP (1) | JP2007530520A (pt) |
| KR (1) | KR20070008651A (pt) |
| CN (1) | CN1997396A (pt) |
| AT (1) | ATE447973T1 (pt) |
| AU (1) | AU2005225197B2 (pt) |
| BR (1) | BRPI0508983A (pt) |
| CA (1) | CA2558598A1 (pt) |
| DE (1) | DE602005017590D1 (pt) |
| ES (1) | ES2335291T3 (pt) |
| GB (1) | GB0406445D0 (pt) |
| IL (1) | IL177953A0 (pt) |
| MX (1) | MXPA06010757A (pt) |
| NO (1) | NO20064754L (pt) |
| NZ (1) | NZ549554A (pt) |
| WO (1) | WO2005092385A2 (pt) |
| ZA (1) | ZA200607554B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| WO2005092384A2 (en) * | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy with azd2171 and a platinum anti-tumour agent |
| BRPI0612397A2 (pt) * | 2005-07-06 | 2011-02-22 | Astrazeneca Ab | uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente |
| ATE502641T1 (de) * | 2005-12-22 | 2011-04-15 | Astrazeneca Ab | Kombination aus azd2171 und pemetrexed |
| RU2349271C2 (ru) * | 2007-03-29 | 2009-03-20 | ФГУ Ростовский научно-исследовательский онкологический институт Росздрава | Способ лечения рака прямой кишки |
| TW200922590A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096331A (en) * | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| DE69735057T2 (de) * | 1996-03-12 | 2006-08-31 | PG-TXL Co., L.P., Houston | Wasserlösliche paclitaxel-prodrogen |
| US6596712B2 (en) * | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
| US6255502B1 (en) * | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
| SK288365B6 (sk) * | 1999-02-10 | 2016-07-01 | Astrazeneca Ab | Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| ATE369894T1 (de) * | 2000-11-22 | 2007-09-15 | Novartis Pharma Gmbh | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| RU2350618C2 (ru) * | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| WO2005092384A2 (en) * | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy with azd2171 and a platinum anti-tumour agent |
| WO2006035203A1 (en) * | 2004-09-27 | 2006-04-06 | Astrazeneca Ab | Cancer combination therapy comprising azd2171 and imatinib |
| BRPI0612397A2 (pt) * | 2005-07-06 | 2011-02-22 | Astrazeneca Ab | uso de azd2171 ou um sal farmaceuticamente aceitável do mesmo e gencitabina, composição farmacêutica, kit, e, método para a produção de um efeito anti-angiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente |
| CA2633211A1 (en) * | 2005-12-15 | 2007-06-21 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| ATE502641T1 (de) * | 2005-12-22 | 2011-04-15 | Astrazeneca Ab | Kombination aus azd2171 und pemetrexed |
-
2004
- 2004-03-23 GB GBGB0406445.7A patent/GB0406445D0/en not_active Ceased
-
2005
- 2005-03-22 DE DE602005017590T patent/DE602005017590D1/de not_active Expired - Lifetime
- 2005-03-22 KR KR1020067021967A patent/KR20070008651A/ko not_active Ceased
- 2005-03-22 MX MXPA06010757A patent/MXPA06010757A/es active IP Right Grant
- 2005-03-22 US US10/594,234 patent/US20070135462A1/en not_active Abandoned
- 2005-03-22 AU AU2005225197A patent/AU2005225197B2/en not_active Ceased
- 2005-03-22 CA CA002558598A patent/CA2558598A1/en not_active Abandoned
- 2005-03-22 WO PCT/GB2005/001089 patent/WO2005092385A2/en not_active Ceased
- 2005-03-22 BR BRPI0508983-2A patent/BRPI0508983A/pt not_active IP Right Cessation
- 2005-03-22 JP JP2007504471A patent/JP2007530520A/ja active Pending
- 2005-03-22 CN CNA2005800092163A patent/CN1997396A/zh active Pending
- 2005-03-22 AT AT05729377T patent/ATE447973T1/de not_active IP Right Cessation
- 2005-03-22 NZ NZ549554A patent/NZ549554A/en unknown
- 2005-03-22 ES ES05729377T patent/ES2335291T3/es not_active Expired - Lifetime
- 2005-03-22 EP EP05729377A patent/EP1729807B1/en not_active Expired - Lifetime
-
2006
- 2006-09-07 IL IL177953A patent/IL177953A0/en unknown
- 2006-09-08 ZA ZA200607554A patent/ZA200607554B/en unknown
- 2006-10-20 NO NO20064754A patent/NO20064754L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20064754L (no) | 2006-10-20 |
| WO2005092385A3 (en) | 2006-11-02 |
| AU2005225197B2 (en) | 2008-10-09 |
| JP2007530520A (ja) | 2007-11-01 |
| KR20070008651A (ko) | 2007-01-17 |
| NZ549554A (en) | 2009-12-24 |
| DE602005017590D1 (de) | 2009-12-24 |
| ATE447973T1 (de) | 2009-11-15 |
| WO2005092385A2 (en) | 2005-10-06 |
| HK1096022A1 (en) | 2007-05-25 |
| EP1729807A2 (en) | 2006-12-13 |
| IL177953A0 (en) | 2006-12-31 |
| EP1729807B1 (en) | 2009-11-11 |
| CN1997396A (zh) | 2007-07-11 |
| CA2558598A1 (en) | 2005-10-06 |
| GB0406445D0 (en) | 2004-04-28 |
| AU2005225197A1 (en) | 2005-10-06 |
| ZA200607554B (en) | 2008-05-28 |
| ES2335291T3 (es) | 2010-03-24 |
| MXPA06010757A (es) | 2006-12-15 |
| US20070135462A1 (en) | 2007-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1551409T1 (sl) | Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka | |
| CY1111547T1 (el) | Συνδυασμος zd6474 και πεμετρεξεδης | |
| CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
| MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
| MXPA05008583A (es) | Terapia de combinacion de zd6474 con 5-fu y/o cpt-11. | |
| BRPI0508983A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluido um sal de maleato de azd2171 e um taxano, composição farmacêutica, kit, e, método para a produção de efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente tal como um ser humano | |
| PL1653964T3 (pl) | Skojarzone leczenie raka obejmujące AZD2171 i ZD1839 | |
| BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
| BRPI0412450A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular em um animal de sangue quente tal como um ser humano, e para o tratamento de um cáncer, composição farmacêutica, kit, e, uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd6126 ou um sal farmaceuticamente aceitável deste | |
| WO2005092384A3 (en) | Combination therapy with azd2171 and a platinum anti-tumour agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2136 DE 13/12/2011. |